Bond Relief Fades

Bigger bond buybacks brought one day of relief before long-term yields started climbing again.

Author

Elie Zakhour
August 21, 2026

Market Snapshot

Get a Top Job Offer, Guaranteed (or tuition is free) | Apply Here

Market News

US stocks and bonds fell as investors questioned whether the Treasury’s efforts to contain borrowing costs can provide anything more than temporary relief. The S&P 500 dropped 0.9%, while 30-year Treasury yields resumed their climb despite Treasury Secretary Scott Bessent signaling potentially larger bond buybacks and an upcoming fiscal-consolidation plan. Higher energy prices added to inflation concerns, with WTI settling near $88 and Brent above $93 after President Trump threatened severe economic consequences for countries supporting Iran. Walmart also weighed on equities after disappointing sales sent the stock to its steepest decline since 2022, while Bitcoin bucked the risk-off mood by climbing above $72,000.

Source: YahooFinance

The bigger issue remains America’s long-term borrowing burden. Treasury buybacks may improve market liquidity and temporarily relieve pressure on yields, but investors remain skeptical that they can offset persistent fiscal deficits and heavy government financing needs without meaningful deficit reduction. Meanwhile, the AI investment boom continues to generate enormous financing requirements, with Broadcom reportedly seeking more than $60 billion of debt for an AI-chip financing deal, while Anthropic is said to expect the size of its IPO to match or exceed SpaceX’s record share sale. Fed officials remain cautious, but the July minutes showed a September rate hike remains possible if inflation fails to decline.

Peel Take: The Treasury can buy bonds, but buybacks alone won’t solve the broader borrowing problem. They may calm the market temporarily, but sustainably lower long-term yields probably require investors to see a more credible path for deficits and government financing needs. Add heavy AI capex demand and $88 oil into the equation, and the market’s “lower rates are coming” story suddenly looks a lot less comfortable.

What's Ripe

Strategy Inc. (MSTR) 7.81% 

  • Strategy jumped 7.8% as crypto-linked stocks rallied following President Trump's push for Congress to pass a "fair version" of the Clarity Act, while Treasury's expanded long-bond buybacks also helped risk appetite. Bitcoin crossed $70,000 for the first time since June.

  • Peel Take: Crypto loves two things: rising prices and hopes for regulatory clarity, and Thursday delivered both. Clearer rules could reduce regulatory uncertainty and encourage greater institutional participation, while Strategy remains a high-beta proxy for Bitcoin, meaning crypto rallies tend to get amplified in its shares.

CF Industries Holdings Inc. (CF) 5.61% 

  • CF Industries rose 5.61%, extending its strong year-to-date run as tensions surrounding the Strait of Hormuz raised concerns about global fertilizer supplies. The Middle East normally accounts for a significant share of globally traded nitrogen fertilizer, including ammonia and urea.

  • Peel Take: Hormuz isn’t just an oil story it’s also an agriculture story. Any disruption to fertilizer shipments could tighten global supply and push nitrogen prices higher, benefiting producers like CF Industries. But after a 63% rally this year, the stock is increasingly tied to how long these geopolitical supply fears persist.

What's Rotten

Moderna Inc. (MRNA) 23.55%

  • Sank 23.5%, making it the worst-performing stock in the S&P 500, as investors locked in profits following Wednesday’s extraordinary 177% surge. The previous rally came after Moderna and Merck reported that their personalized cancer vaccine, combined with Merck’s Keytruda, reduced the risk of melanoma returning or spreading. Merck slipped 2.1% after gaining 12.6% the day before.

  • Peel Take: After a 177% one-day explosion, a sharp pullback wasn’t surprising as traders cashed in. The 23.5% decline looks more like profit-taking than a reversal of the cancer-vaccine story. Investors will now shift their attention from the initial clinical excitement toward whether the treatment can clear regulatory hurdles and ultimately become a meaningful commercial product.

Walmart Inc. (WMT) 9.15%

  • Tumbled 9.2% despite beating second-quarter earnings estimates and raising its full-year sales and profit outlook. The problem: third-quarter earnings guidance came in below Wall Street expectations, while US comparable-store sales grew just 2.6%, versus 3.8% expected, the weakest quarterly pace in six years.

  • Peel Take: Walmart didn’t necessarily have a bad quarter; it simply wasn’t good enough for the expectations baked into the stock. Slowing comparable sales also offer another warning that US consumers may be becoming more cautious, making Walmart an important bellwether for whether the broader consumer slowdown is gaining momentum.

🧠 Technical Trip

Interview Q&A from Rothschild & Co

👉 Want 1-on-1 recruiting help from Rothschild & Co bankers & 5,000+ top mentors? Apply to WSO Academy

🦈 Deal Dispatch

M&A, IPOs, And Other Notable Transactions

Student Success Corner

Banana Brain Teaser

Previous

A company has $500 million of annual revenue and $75 million of accounts receivable. Approximately what is its DSO?

Answer: ~ 55 days

Today

An investor puts $40,000 into an asset that rises 15%, then withdraws $10,000. How much money remains invested?

❝

The essence of investment management is the management of risks, not the management of returns.

Benjamin Graham

How Would You Rate Today's Peel?


Happy Investing,
Chris, Elie, Mitchell, Fernanda, Nick, & Patrick